Free Trial
NASDAQ:WGS

GeneDx (WGS) Stock Price, News & Analysis

GeneDx logo
$128.72 +3.65 (+2.92%)
As of 11:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About GeneDx Stock (NASDAQ:WGS)

Advanced

Key Stats

Today's Range
$126.00
$130.61
50-Day Range
$107.74
$132.54
52-Week Range
$55.17
$136.00
Volume
135,509 shs
Average Volume
936,906 shs
Market Capitalization
$3.70 billion
P/E Ratio
2,577.26
Dividend Yield
N/A
Price Target
$112.80
Consensus Rating
Moderate Buy

Company Overview

GeneDx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

WGS MarketRank™: 

GeneDx scored higher than 58% of companies evaluated by MarketBeat, and ranked 425th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 8 buy ratings, 3 hold ratings, and 1 sell rating.

  • Downside Risk

    GeneDx has a consensus price target of $112.80, representing about 9.8% downside from its current price of $125.07.

  • Amount of Analyst Coverage

    GeneDx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about GeneDx's stock forecast and price target.
  • Earnings Growth

    Earnings for GeneDx are expected to grow by 115.46% in the coming year, from $0.97 to $2.09 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GeneDx is 2,501.40, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 82.65.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GeneDx is 2,501.40, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.65.

  • Price to Book Value per Share Ratio

    GeneDx has a P/B Ratio of 14.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about GeneDx's valuation and earnings.
  • Percentage of Shares Shorted

    11.20% of the float of GeneDx has been sold short.
  • Short Interest Ratio / Days to Cover

    GeneDx has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in GeneDx has recently decreased by 21.88%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    GeneDx does not currently pay a dividend.

  • Dividend Growth

    GeneDx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.20% of the float of GeneDx has been sold short.
  • Short Interest Ratio / Days to Cover

    GeneDx has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in GeneDx has recently decreased by 21.88%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    GeneDx has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for GeneDx this week, compared to 12 articles on an average week.
  • Search Interest

    8 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $67,489,314.00 in company stock.

  • Percentage Held by Insiders

    29.60% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about GeneDx's insider trading history.
Receive WGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

WGS Stock News Headlines

An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
4 Analysts Assess GeneDx Holdings: What You Need To Know
GeneDx initiated with a Buy at Canaccord
See More Headlines

WGS Stock Analysis - Frequently Asked Questions

GeneDx's stock was trading at $76.86 at the start of the year. Since then, WGS stock has increased by 62.7% and is now trading at $125.07.

GeneDx Holdings Corp. (NASDAQ:WGS) released its quarterly earnings results on Tuesday, July, 29th. The company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.40. The company had revenue of $102.69 million for the quarter, compared to analysts' expectations of $86 million. GeneDx had a trailing twelve-month return on equity of 16.51% and a net margin of 0.39%.
Read the conference call transcript
.

GeneDx shares reverse split on Thursday, May 4th 2023.The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Top institutional investors of GeneDx include Voya Investment Management LLC (0.41%), Peregrine Capital Management LLC (0.26%), Calamos Advisors LLC (0.16%) and Simplify Asset Management Inc. (0.05%). Insiders that own company stock include Keith A Meister, Casdin Capital, Llc, School Of Medicine At Mo Icahn, Opko Health, Inc, Kareem Saad, Richard C Pfenniger Jr, Richard C Pfenniger Jr, Katherine Stueland, Jason Ryan, Kevin Feeley and Karen Ann White.
View institutional ownership trends
.

Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

Last Earnings
7/29/2025
Today
10/24/2025
Next Earnings (Estimated)
10/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Services
Sub-Industry
Healthcare
Current Symbol
NASDAQ:WGS
CIK
1818331
Fax
N/A
Employees
1,200
Year Founded
2000

Price Target and Rating

High Price Target
$155.00
Low Price Target
$80.00
Potential Upside/Downside
-13.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.58
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.05
Trailing P/E Ratio
2,602.88
Forward P/E Ratio
134.69
P/E Growth
N/A
Net Income
-$52.29 million
Net Margins
0.39%
Pretax Margin
0.42%
Return on Equity
16.51%
Return on Assets
9.35%

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
2.87
Quick Ratio
2.70

Sales & Book Value

Annual Sales
$362.32 million
Price / Sales
10.36
Cash Flow
$1.10 per share
Price / Cash Flow
118.26
Book Value
$8.75 per share
Price / Book
14.93

Miscellaneous

Outstanding Shares
28,726,000
Free Float
20,223,000
Market Cap
$3.75 billion
Optionable
Optionable
Beta
1.98

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:WGS) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners